Novavax (NVAX) EBITDA (2010 - 2026)

Novavax's EBITDA history runs 17 years deep, the most recent figure standing at -$15.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 102.99% year-over-year to -$15.4 million; the TTM figure through Mar 2026 stood at -$78.1 million (down 119.0% YoY), while the FY2025 annual figure was $452.8 million, up 281.9% from the prior year.
• EBITDA for Q1 2026 stood at -$15.4 million, down from $14.2 million in the prior quarter.
• The five-year high for EBITDA was $515.5 million in Q1 2025, with the low at -$483.0 million in Q2 2022.
• The 5-year median for EBITDA is -$127.2 million (2022), against an average of -$60.2 million.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 249.44% in 2023, then surged 455.94% in 2025.
• Novavax's EBITDA stood at -$243.9 million in 2022, then climbed by 24.73% to -$183.6 million in 2023, then grew by 28.59% to -$131.1 million in 2024, then soared by 110.86% to $14.2 million in 2025, then plunged by 208.43% to -$15.4 million in 2026.
• Business Quant data shows NVAX's EBITDA at -$15.4 million in Q1 2026, $14.2 million in Q4 2025, and -$178.0 million in Q3 2025.